



Yamhill County
Health and Human Services
Public Health

To: Health Care Providers in Yamhill County

From: Yamhill County Public Health

ALERT

Date: **12/05/2024**

**COPY AND DISTRIBUTE TO
Health Care Providers**

Regarding: **Clinicians should begin offering
nirsevimab to prevent RSV infection**

Phone number for follow-up: **(503) 434-7483**



State of Oregon
Health Alert Network

There is early evidence of increasing respiratory syncytial virus (RSV) activity in Oregon. Although we have not yet reached RSV season onset criteria, now is the time to begin administering nirsevimab (Beyfortus®), the immunization which prevents severe RSV infection. Clinicians should continue to offer nirsevimab through the end of the RSV season in Oregon. Each year, 2-3% of all infants are hospitalized for RSV. [Last season, nirsevimab was 90% effective at protecting infants from RSV-associated hospitalization.](#)

The Centers for Disease Control and Prevention (CDC) recommend nirsevimab for all infants* younger than 8 months of age born during or entering their first RSV season. Nirsevimab is also recommended for children 8-19 months of age at increased risk for severe RSV disease and entering their second RSV season.

Children at increased risk for severe RSV entering their second RSV season include:

1. Children who have chronic lung disease from being born premature who required medical therapy for their lung disease in the last 6 months
2. Children who are severely immunocompromised
3. Children with cystic fibrosis who have severe lung disease
4. American Indian and Alaska Native children, who experience disproportionately high rates of RSV-associated hospitalization

Additional information regarding RSV in infants and young children is available at: <https://www.cdc.gov/rsv/infants-young-children/>.

Nirsevimab is covered at no cost by the [Vaccines for Children](#) program.

*CDC recommends one of two immunizations to protect infants from severe RSV—nirsevimab or the maternal RSV vaccine given to those who are 32-36 weeks pregnant during September through January. Most infants do not require both.

For questions regarding nirsevimab, please contact vfc.help@odhsoha.oregon.gov.

This HAN notification was sent to the following alert lists: ORCD1 (includes: Tribal and local health administrators and health officers, CD Nurses, hospitals, preparedness coordinators, labs, epidemiologists, and some members of OHA's staff and leadership), and County/Tribe Emergency Managers.

Unless otherwise noted, feel free to share this HAN notification with:

- Others within your organization.
- Professionals within your health, preparedness, and response affiliations.

Oregon 24/7 disease reporting: 971-673-1111